Head of non-profit paid nearly $900,000 a year despite failure of federal ‘axe the fax’ program

Canada Health Infoway disclosed that CEO Michael Green received $884,114 in total compensation in fiscal 2024-25, including $616,700 of base salary and $215,845 in bonuses, as its $300-million PrescribeIT digital prescription program is being shut down after fewer than 5% of prescriptions used it. The organization also reported nearly $29-million in total remuneration for 175 employees plus $2.9-million in severance. The disclosure has triggered criticism from Conservative MPs and renewed calls for an auditor-general investigation.

Analysis

This is less about one program failure than about a governance discount being applied to a broader ecosystem of quasi-public health-tech spend. When a federally backed non-profit can pay outsized comp for weak adoption, the second-order effect is tighter procurement scrutiny across digital health, e-prescribing, and any vendor selling “workflow modernization” to governments; that creates a multi-quarter pause in new awards and a higher hurdle for renewals. The immediate loser is the vendor/implementation layer that depended on continued rollout support, but the bigger loser is the political appetite for incremental digitization projects that require clinician behavior change rather than pure infrastructure.

The key market implication is not a direct revenue hit but a delay in budget release. Expect provinces and ministries to slow-change digital health commitments for 1-2 quarters while auditors and committees reset governance rules, which should pressure smaller Canadian health IT names with public-sector exposure more than diversified peers. Conversely, firms selling compliance, audit, cybersecurity, and workflow integration into healthcare should see a modest bid as institutions try to prove control and measurable adoption before spending again.

The contrarian view is that the headline is noisy but the spending model may ultimately become more efficient, not less: once political cover is removed from vanity programs, capital can be reallocated to narrower use cases with clearer ROI. If that happens, the next cycle could favor vendors with measurable pharmacy-system integration and high physician adoption, rather than broad platform plays. The tail risk is a much broader fiscal clampdown on innovation grants if this becomes a symbol of waste, which would extend the pressure from months into a multi-year procurement winter.

Key Decisions for Investors

• Short Canadian public-sector digital health exposure on any liquid proxy or diversified software basket with government IT revenue; hold 1-3 months and cover into any auditor-general announcement risk, as governance headlines can compress multiples 10-15% before fundamentals reset.
• Long cybersecurity / compliance software with healthcare and government exposure (e.g., CRWD, VEEV, OKTA on pullbacks) for 2-4 quarters; the trade works if agencies shift spend from transformation to control, with upside from budget reallocation rather than net-new demand.
• Pair trade: long CA-focused hospital supply-chain / workflow names with measurable adoption, short grant-dependent healthcare IT names; target 8-12% relative outperformance over the next 6 months as procurement turns evidence-based.
• Avoid initiating new long positions in Canadian digital-government contractors until after the audit / committee process clears; the risk-reward is unfavorable because reputational overhang can persist longer than the operational fix.
• If a broad Canadian healthcare innovation selloff develops, selectively buy the strongest platforms on 15-20% drawdowns, but only those with recurring private-sector revenue and low government concentration; the contrarian setup is that this scandal may cleanse the sector rather than kill it.